BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35653034)

  • 21. The role of the tumor suppressor RUNX3 in giant cell tumor of the bone.
    Han YX; Liang DY
    Int J Oncol; 2012 Mar; 40(3):673-8. PubMed ID: 22076387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells.
    Fellenberg J; Sähr H; Mancarella D; Plass C; Lindroth AM; Westhauser F; Lehner B; Ewerbeck V
    Cancer Lett; 2019 Apr; 448():61-69. PubMed ID: 30742944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma.
    Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2021 Mar; 34(2):688-697. PubMed ID: 33205363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
    Ratnagiri R; Uppin S
    J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Giant-cell-poor giant cell tumor of bone: report of two cases and literature review.
    Yakoub MA; Torrence D; Hwang S; Bartelstein M; Healey JH; Hameed M
    Skeletal Radiol; 2023 Sep; 52(9):1791-1798. PubMed ID: 36781420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone.
    Oyama R; Takahashi M; Kito F; Sakumoto M; Shiozawa K; Qiao Z; Yoshida A; Endo M; Kawai A; Kondo T
    In Vitro Cell Dev Biol Anim; 2018 Jun; 54(6):458-467. PubMed ID: 29845452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
    Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
    Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
    Yamamoto H; Ishihara S; Toda Y; Oda Y
    Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-Wide Transcriptome Profiling of the Neoplastic Giant Cell Tumor of Bone Stromal Cells by RNA Sequencing.
    Lau CP; Kwok JS; Tsui JC; Huang L; Yang KY; Tsui SK; Kumta SM
    J Cell Biochem; 2017 Jun; 118(6):1349-1360. PubMed ID: 27862217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drivers underpinning the malignant transformation of giant cell tumour of bone.
    Fittall MW; Lyskjaer I; Ellery P; Lombard P; Ijaz J; Strobl AC; Oukrif D; Tarabichi M; Sill M; Koelsche C; Mechtersheimer G; Demeulemeester J; Tirabosco R; Amary F; Campbell PJ; Pfister SM; Jones DT; Pillay N; Van Loo P; Behjati S; Flanagan AM
    J Pathol; 2020 Dec; 252(4):433-440. PubMed ID: 32866294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
    Tsukamoto Y; Futani H; Kihara T; Watanabe T; Kumanishi S; Matsuo S; Hirota S; Ueda T; Yamamoto H; Yoshiya S
    Pathol Res Pract; 2018 Sep; 214(9):1504-1509. PubMed ID: 29970305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment and characterization of NCC-LMS3-C1: a novel patient-derived cell line of leiomyosarcoma.
    Yoshimatsu Y; Noguchi R; Osaki J; Sin Y; Tsuchiya R; Ono T; Akiyama T; Adachi Y; Tanzawa Y; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2024 Jan; 37(1):337-344. PubMed ID: 37907774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
    Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
    Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway.
    Lübbehüsen C; Lüke J; Seeling C; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Möller P; Barth TFE
    Sci Rep; 2019 Apr; 9(1):6458. PubMed ID: 31015476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Sei A; Takeshita F; Sugaya J; Iwata S; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 Jul; 34(4):1266-1273. PubMed ID: 33990915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
    Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
    J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment and characterization of NCC-MRT1-C1: a novel cell line of malignant rhabdoid tumor.
    Akiyama T; Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Sato C; Kojima N; Yoshida A; Kawai A; Ohtori S; Kondo T
    Hum Cell; 2022 Nov; 35(6):2002-2010. PubMed ID: 35927606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simvastatin Possesses Antitumor and Differentiation-Promoting Properties That Affect Stromal Cells in Giant Cell Tumor of Bone.
    Lau CPY; Fung CSH; Wong KC; Wang YH; Huang L; Tsui SKW; Lee OK; Kumta SM
    J Orthop Res; 2020 Feb; 38(2):297-310. PubMed ID: 31471919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
    Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
    Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.